Bahrani, Ahmed A; Abner, Erin L; DeCarli, Charles S; Barber, Justin M; Sutton, Abigail C; Maillard, Pauline; Sandoval, Francisco; Arfanakis, Konstantinos; Yang, Yung-Chuan; Evia, Arnold M; Schneider, Julie A; Habes, Mohamad; Franklin, Crystal G; Seshadri, Sudha; Satizabal, Claudia L; Caprihan, Arvind; Thompson, Jeffrey F; Rosenberg, Gary A; Wang, Danny JJ; Jann, Kay; Zhao, Chenyang; Lu, Hanzhang; Rosenberg, Paul B; Albert, Marilyn S; Ali, Doaa G; Singh, Herpreet; Schwab, Kristin; Greenberg, Steven M; Helmer, Karl G; Powel, David K; Gold, Brian T; Goldstein, Larry B; Wilcock, Donna M; Jicha, Gregory A

doi:10.3233/jad-230629

Download PDF

Multi-Site Cross-Site Inter-Rater and Test-Retest Reliability and Construct Validity of the MarkVCID White Matter Hyperintensity Growth and Regression Protocol.

Published Web Location

https://doi.org/10.3233/jad-230629

Abstract

Background

White matter hyperintensities (WMH) that occur in the setting of vascular cognitive impairment and dementia (VCID) may be dynamic increasing or decreasing volumes or stable over time. Quantifying such changes may prove useful as a biomarker for clinical trials designed to address vascular cognitive-impairment and dementia and Alzheimer's Disease.

Objective

Conducting multi-site cross-site inter-rater and test-retest reliability of the MarkVCID white matter hyperintensity growth and regression protocol.

Methods

The NINDS-supported MarkVCID Consortium evaluated a neuroimaging biomarker developed to track WMH change. Test-retest and cross-site inter-rater reliability of the protocol were assessed. Cognitive test scores were analyzed in relation to WMH changes to explore its construct validity.

Results

ICC values for test-retest reliability of WMH growth and regression were 0.969 and 0.937 respectively, while for cross-site inter-rater ICC values for WMH growth and regression were 0.995 and 0.990 respectively. Word list long-delay free-recall was negatively associated with WMH growth (p < 0.028) but was not associated with WMH regression.

Conclusions

The present data demonstrate robust ICC validity of a WMH growth/regression protocol over a one-year period as measured by cross-site inter-rater and test-retest reliability. These data suggest that this approach may serve an important role in clinical trials of disease-modifying agents for VCID that may preferentially affect WMH growth, stability, or regression.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content

For improved accessibility of PDF content, download the file to your device.

UC Davis